Bortezomib
Generic Name: bortezomib
Brand Names:
Bortezomib
Bortezomib is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Overview
Bortezomib is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Uses
Indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Dosage
The recommended starting dose is 1.3 mg/m2 administered as a 3 to 5 second bolus intravenous injection or subcutaneous injection. For intravenous or subcutaneous use only.
Side Effects
Most commonly reported adverse reactions (20% or more) include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia.
Warnings
Peripheral neuropathy, hypotension, cardiac toxicity, pulmonary toxicity, posterior reversible encephalopathy syndrome, gastrointestinal toxicity, thrombocytopenia/neutropenia, tumor lysis syndrome, hepatic toxicity, thrombotic microangiopathy, and embryo-fetal toxicity require monitoring and potential dose modification. Contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol, and for intrathecal administration.
Storage
Store unopened vials in original package protected from light. Administer reconstituted product within eight hours.
Frequently Asked Questions
What is Bortezomib used for?▼
Indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.
What are the side effects of Bortezomib?▼
Most commonly reported adverse reactions (20% or more) include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia.
What are the important warnings for Bortezomib?▼
Peripheral neuropathy, hypotension, cardiac toxicity, pulmonary toxicity, posterior reversible encephalopathy syndrome, gastrointestinal toxicity, thrombocytopenia/neutropenia, tumor lysis syndrome, hepatic toxicity, thrombotic microangiopathy, and embryo-fetal toxicity require monitoring and potential dose modification. Contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol, and for intrathecal administration.
Related Medications
1236-ccantifungal Powder(talc Free)
1236-ccantifungal powder(talc free)
Purpose Antifungal
Infliximab 40.0 Mg/ml Drug Substance
infliximab 40.0 mg/ml drug substance
Dosage form: LIQUID. Active ingredients: INFLIXIMAB (REMICADE) (40 mg/mL). Category: DRUG FOR FURTHER PROCESSING.
Broad Spectrum Spf 15 Sunscreen Iced Pear Lip Balm
broad spectrum spf 15 sunscreen iced pear lip balm
Purpose Sunscreen
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.